the invention relates to novel inhibitors of the chymotrypsin like activity of imunoproteasoma (inhibition beta5i subunit or subunit lmp7) of formula i, in which they are defined in the description substituente meaning, in the form of pure enantiomers or mixtures of enantiomers and their pharmaceutically acceptable salts.the invention relates to the use of these compounds for the treatment of disorders characterised by increased activity imunoproteasoma.Izum se nanaša na nove zaviralce kimotripsinske aktivnosti imunoproteasoma (zaviranje podenote beta5i oziroma podenote LMP7) s formulo I, v kateri imajo substituente v opisu definiran pomen, v obliki čistih enantiomerov ali zmesi enantiomerov in njihovih farmacevtsko sprejemljivih soli. Izum se nanaša na uporabo teh spojin za zdravljenje bolezni, za katere je značilna povečana aktivnost imunoproteasoma.
